Global Premenstrual Syndrome Market 2024-2028

PUBLISHED: January 3, 2024

PAGES: 158 Pages

DELIVERY TIME: 1-2 business days

ADD TO COMPARE

SELECT AN OPTION

The premenstrual syndrome market is forecasted to grow by USD 276.72 mn during 2023-2028, accelerating at a CAGR of 3.69% during the forecast period. The report on the premenstrual syndrome market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing awareness and reporting about PMS, collaboration and partnerships among vendors, and growing preference for herbal and dietary supplements.

Technavio's premenstrual syndrome market is segmented as below:

Market Scope
Base Year	2024
End Year	2028
Series Year	2024-2028
Growth Momentum	Accelerate
YOY 2024	3.22%
CAGR	3.69%
Incremental Value	$276.72mn

By Drug Class

Analgesics
Oral contraceptives & ovarian suppression agents
Antidepressants
Others

By Distribution Channel

Retail pharmacies
Hospital pharmacies
Online pharmacies

By Geographical Landscape

North America
Europe
Asia
Rest of World (ROW)

This study identifies the robust adoption of telemedicine as one of the prime reasons driving the premenstrual syndrome market growth during the next few years. Also, high investment on r and d on PMS drugs and menstrual health initiatives by regional governments will lead to sizable demand in the market.

The report on the premenstrual syndrome market covers the following areas:

Premenstrual syndrome market sizing
Premenstrual syndrome market forecast
Premenstrual syndrome market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading premenstrual syndrome market vendors that include AbbVie Inc., Aspen Pharmacare Holdings Ltd, Bayer AG, Bristol Myers Squibb Co., Eli Lilly and Co., GlaxoSmithKline Plc, Herbalife International of America Inc., Hikma Pharmaceuticals Plc, Johnson and Johnson, Lupin Ltd., Merck KGaA, Novartis AG, Octavius Pharma Pvt. Ltd., Otsuka Pharmaceutical Co. Ltd., Pfizer Inc., Recordati S.p.A, Sanofi SA, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Viatris Inc.. Also, the premenstrual syndrome market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Product Code: IRTNTR77208

1 Executive Summary

1.1 Market overview
Exhibit 01: Executive Summary - Chart on Market Overview
Exhibit 02: Executive Summary - Data Table on Market Overview
Exhibit 03: Executive Summary - Chart on Global Market Characteristics
Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
Exhibit 05: Executive Summary - Chart on Market Segmentation by Drug Class
Exhibit 06: Executive Summary - Chart on Market Segmentation by Distribution Channel
Exhibit 07: Executive Summary - Chart on Incremental Growth
Exhibit 08: Executive Summary - Data Table on Incremental Growth
Exhibit 09: Executive Summary - Chart on Vendor Market Positioning

2 Market Landscape

2.1 Market ecosystem
Exhibit 10: Parent market
Exhibit 11: Market Characteristics

3 Market Sizing

3.1 Market definition
Exhibit 12: Offerings of vendors included in the market definition
3.2 Market segment analysis
Exhibit 13: Market segments
3.3 Market size 2023
3.4 Market outlook: Forecast for 2023-2028
Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ million)
Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ million)
Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)

4 Historic Market Size

4.1 Global premenstrual syndrome market 2018 - 2022
Exhibit 18: Historic Market Size - Data Table on global premenstrual syndrome market 2018 - 2022 ($ million)
4.2 Drug Class Segment Analysis 2018 - 2022
Exhibit 19: Historic Market Size - Drug Class Segment 2018 - 2022 ($ million)
4.3 Distribution Channel Segment Analysis 2018 - 2022
Exhibit 20: Historic Market Size - Distribution Channel Segment 2018 - 2022 ($ million)
4.4 Geography Segment Analysis 2018 - 2022
Exhibit 21: Historic Market Size - Geography Segment 2018 - 2022 ($ million)
4.5 Country Segment Analysis 2018 - 2022
Exhibit 22: Historic Market Size - Country Segment 2018 - 2022 ($ million)

5 Five Forces Analysis

5.1 Five forces summary
Exhibit 23: Five forces analysis - Comparison between 2023 and 2028
5.2 Bargaining power of buyers
Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
5.3 Bargaining power of suppliers
Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
5.4 Threat of new entrants
Exhibit 26: Threat of new entrants - Impact of key factors in 2023 and 2028
5.5 Threat of substitutes
Exhibit 27: Threat of substitutes - Impact of key factors in 2023 and 2028
5.6 Threat of rivalry
Exhibit 28: Threat of rivalry - Impact of key factors in 2023 and 2028
5.7 Market condition
Exhibit 29: Chart on Market condition - Five forces 2023 and 2028

6 Market Segmentation by Drug Class

6.1 Market segments
Exhibit 30: Chart on Drug Class - Market share 2023-2028 (%)
Exhibit 31: Data Table on Drug Class - Market share 2023-2028 (%)
6.2 Comparison by Drug Class
Exhibit 32: Chart on Comparison by Drug Class
Exhibit 33: Data Table on Comparison by Drug Class
6.3 Analgesics - Market size and forecast 2023-2028
Exhibit 34: Chart on Analgesics - Market size and forecast 2023-2028 ($ million)
Exhibit 35: Data Table on Analgesics - Market size and forecast 2023-2028 ($ million)
Exhibit 36: Chart on Analgesics - Year-over-year growth 2023-2028 (%)
Exhibit 37: Data Table on Analgesics - Year-over-year growth 2023-2028 (%)
6.4 Oral contraceptives and ovarian suppression agents - Market size and forecast 2023-2028
Exhibit 38: Chart on Oral contraceptives and ovarian suppression agents - Market size and forecast 2023-2028 ($ million)
Exhibit 39: Data Table on Oral contraceptives and ovarian suppression agents - Market size and forecast 2023-2028 ($ million)
Exhibit 40: Chart on Oral contraceptives and ovarian suppression agents - Year-over-year growth 2023-2028 (%)
Exhibit 41: Data Table on Oral contraceptives and ovarian suppression agents - Year-over-year growth 2023-2028 (%)
6.5 Antidepressants - Market size and forecast 2023-2028
Exhibit 42: Chart on Antidepressants - Market size and forecast 2023-2028 ($ million)
Exhibit 43: Data Table on Antidepressants - Market size and forecast 2023-2028 ($ million)
Exhibit 44: Chart on Antidepressants - Year-over-year growth 2023-2028 (%)
Exhibit 45: Data Table on Antidepressants - Year-over-year growth 2023-2028 (%)
6.6 Others - Market size and forecast 2023-2028
Exhibit 46: Chart on Others - Market size and forecast 2023-2028 ($ million)
Exhibit 47: Data Table on Others - Market size and forecast 2023-2028 ($ million)
Exhibit 48: Chart on Others - Year-over-year growth 2023-2028 (%)
Exhibit 49: Data Table on Others - Year-over-year growth 2023-2028 (%)
6.7 Market opportunity by Drug Class
Exhibit 50: Market opportunity by Drug Class ($ million)
Exhibit 51: Data Table on Market opportunity by Drug Class ($ million)

7 Market Segmentation by Distribution Channel

7.1 Market segments
Exhibit 52: Chart on Distribution Channel - Market share 2023-2028 (%)
Exhibit 53: Data Table on Distribution Channel - Market share 2023-2028 (%)
7.2 Comparison by Distribution Channel
Exhibit 54: Chart on Comparison by Distribution Channel
Exhibit 55: Data Table on Comparison by Distribution Channel
7.3 Retail pharmacies - Market size and forecast 2023-2028
Exhibit 56: Chart on Retail pharmacies - Market size and forecast 2023-2028 ($ million)
Exhibit 57: Data Table on Retail pharmacies - Market size and forecast 2023-2028 ($ million)
Exhibit 58: Chart on Retail pharmacies - Year-over-year growth 2023-2028 (%)
Exhibit 59: Data Table on Retail pharmacies - Year-over-year growth 2023-2028 (%)
7.4 Hospital pharmacies - Market size and forecast 2023-2028
Exhibit 60: Chart on Hospital pharmacies - Market size and forecast 2023-2028 ($ million)
Exhibit 61: Data Table on Hospital pharmacies - Market size and forecast 2023-2028 ($ million)
Exhibit 62: Chart on Hospital pharmacies - Year-over-year growth 2023-2028 (%)
Exhibit 63: Data Table on Hospital pharmacies - Year-over-year growth 2023-2028 (%)
7.5 Online pharmacies - Market size and forecast 2023-2028
Exhibit 64: Chart on Online pharmacies - Market size and forecast 2023-2028 ($ million)
Exhibit 65: Data Table on Online pharmacies - Market size and forecast 2023-2028 ($ million)
Exhibit 66: Chart on Online pharmacies - Year-over-year growth 2023-2028 (%)
Exhibit 67: Data Table on Online pharmacies - Year-over-year growth 2023-2028 (%)
7.6 Market opportunity by Distribution Channel
Exhibit 68: Market opportunity by Distribution Channel ($ million)
Exhibit 69: Data Table on Market opportunity by Distribution Channel ($ million)

8 Customer Landscape

8.1 Customer landscape overview
Exhibit 70: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

9.1 Geographic segmentation
Exhibit 71: Chart on Market share By Geographical Landscape 2023-2028 (%)
Exhibit 72: Data Table on Market share By Geographical Landscape 2023-2028 (%)
9.2 Geographic comparison
Exhibit 73: Chart on Geographic comparison
Exhibit 74: Data Table on Geographic comparison
9.3 North America - Market size and forecast 2023-2028
Exhibit 75: Chart on North America - Market size and forecast 2023-2028 ($ million)
Exhibit 76: Data Table on North America - Market size and forecast 2023-2028 ($ million)
Exhibit 77: Chart on North America - Year-over-year growth 2023-2028 (%)
Exhibit 78: Data Table on North America - Year-over-year growth 2023-2028 (%)
9.4 Europe - Market size and forecast 2023-2028
Exhibit 79: Chart on Europe - Market size and forecast 2023-2028 ($ million)
Exhibit 80: Data Table on Europe - Market size and forecast 2023-2028 ($ million)
Exhibit 81: Chart on Europe - Year-over-year growth 2023-2028 (%)
Exhibit 82: Data Table on Europe - Year-over-year growth 2023-2028 (%)
9.5 Asia - Market size and forecast 2023-2028
Exhibit 83: Chart on Asia - Market size and forecast 2023-2028 ($ million)
Exhibit 84: Data Table on Asia - Market size and forecast 2023-2028 ($ million)
Exhibit 85: Chart on Asia - Year-over-year growth 2023-2028 (%)
Exhibit 86: Data Table on Asia - Year-over-year growth 2023-2028 (%)
9.6 Rest of World (ROW) - Market size and forecast 2023-2028
Exhibit 87: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
Exhibit 88: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
Exhibit 89: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
Exhibit 90: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
9.7 US - Market size and forecast 2023-2028
Exhibit 91: Chart on US - Market size and forecast 2023-2028 ($ million)
Exhibit 92: Data Table on US - Market size and forecast 2023-2028 ($ million)
Exhibit 93: Chart on US - Year-over-year growth 2023-2028 (%)
Exhibit 94: Data Table on US - Year-over-year growth 2023-2028 (%)
9.8 Germany - Market size and forecast 2023-2028
Exhibit 95: Chart on Germany - Market size and forecast 2023-2028 ($ million)
Exhibit 96: Data Table on Germany - Market size and forecast 2023-2028 ($ million)
Exhibit 97: Chart on Germany - Year-over-year growth 2023-2028 (%)
Exhibit 98: Data Table on Germany - Year-over-year growth 2023-2028 (%)
9.9 China - Market size and forecast 2023-2028
Exhibit 99: Chart on China - Market size and forecast 2023-2028 ($ million)
Exhibit 100: Data Table on China - Market size and forecast 2023-2028 ($ million)
Exhibit 101: Chart on China - Year-over-year growth 2023-2028 (%)
Exhibit 102: Data Table on China - Year-over-year growth 2023-2028 (%)
9.10 UK - Market size and forecast 2023-2028
Exhibit 103: Chart on UK - Market size and forecast 2023-2028 ($ million)
Exhibit 104: Data Table on UK - Market size and forecast 2023-2028 ($ million)
Exhibit 105: Chart on UK - Year-over-year growth 2023-2028 (%)
Exhibit 106: Data Table on UK - Year-over-year growth 2023-2028 (%)
9.11 Japan - Market size and forecast 2023-2028
Exhibit 107: Chart on Japan - Market size and forecast 2023-2028 ($ million)
Exhibit 108: Data Table on Japan - Market size and forecast 2023-2028 ($ million)
Exhibit 109: Chart on Japan - Year-over-year growth 2023-2028 (%)
Exhibit 110: Data Table on Japan - Year-over-year growth 2023-2028 (%)
9.12 Market opportunity By Geographical Landscape
Exhibit 111: Market opportunity By Geographical Landscape ($ million)
Exhibit 112: Data Tables on Market opportunity By Geographical Landscape ($ million)

10 Drivers, Challenges, and Trends

10.1 Market drivers
10.2 Market challenges
10.3 Impact of drivers and challenges
Exhibit 113: Impact of drivers and challenges in 2023 and 2028
10.4 Market trends

11 Vendor Landscape

11.1 Overview
11.2 Vendor landscape
Exhibit 114: Overview on Criticality of inputs and Factors of differentiation
11.3 Landscape disruption
Exhibit 115: Overview on factors of disruption
11.4 Industry risks
Exhibit 116: Impact of key risks on business

12 Vendor Analysis

12.1 Vendors covered
Exhibit 117: Vendors covered
12.2 Market positioning of vendors
Exhibit 118: Matrix on vendor position and classification
12.3 AbbVie Inc.
Exhibit 119: AbbVie Inc. - Overview
Exhibit 120: AbbVie Inc. - Product / Service
Exhibit 121: AbbVie Inc. - Key news
Exhibit 122: AbbVie Inc. - Key offerings
12.4 Bayer AG
Exhibit 123: Bayer AG - Overview
Exhibit 124: Bayer AG - Business segments
Exhibit 125: Bayer AG - Key news
Exhibit 126: Bayer AG - Key offerings
Exhibit 127: Bayer AG - Segment focus
12.5 Eli Lilly and Co.
Exhibit 128: Eli Lilly and Co. - Overview
Exhibit 129: Eli Lilly and Co. - Product / Service
Exhibit 130: Eli Lilly and Co. - Key news
Exhibit 131: Eli Lilly and Co. - Key offerings
12.6 GlaxoSmithKline Plc
Exhibit 132: GlaxoSmithKline Plc - Overview
Exhibit 133: GlaxoSmithKline Plc - Business segments
Exhibit 134: GlaxoSmithKline Plc - Key news
Exhibit 135: GlaxoSmithKline Plc - Key offerings
Exhibit 136: GlaxoSmithKline Plc - Segment focus
12.7 Herbalife International of America Inc.
Exhibit 137: Herbalife International of America Inc. - Overview
Exhibit 138: Herbalife International of America Inc. - Product / Service
Exhibit 139: Herbalife International of America Inc. - Key offerings
12.8 Johnson and Johnson
Exhibit 140: Johnson and Johnson - Overview
Exhibit 141: Johnson and Johnson - Business segments
Exhibit 142: Johnson and Johnson - Key news
Exhibit 143: Johnson and Johnson - Key offerings
Exhibit 144: Johnson and Johnson - Segment focus
12.9 Lupin Ltd.
Exhibit 145: Lupin Ltd. - Overview
Exhibit 146: Lupin Ltd. - Product / Service
Exhibit 147: Lupin Ltd. - Key news
Exhibit 148: Lupin Ltd. - Key offerings
12.10 Merck KGaA
Exhibit 149: Merck KGaA - Overview
Exhibit 150: Merck KGaA - Business segments
Exhibit 151: Merck KGaA - Key news
Exhibit 152: Merck KGaA - Key offerings
Exhibit 153: Merck KGaA - Segment focus
12.11 Novartis AG
Exhibit 154: Novartis AG - Overview
Exhibit 155: Novartis AG - Business segments
Exhibit 156: Novartis AG - Key offerings
Exhibit 157: Novartis AG - Segment focus
12.12 Octavius Pharma Pvt. Ltd.
Exhibit 158: Octavius Pharma Pvt. Ltd. - Overview
Exhibit 159: Octavius Pharma Pvt. Ltd. - Product / Service
Exhibit 160: Octavius Pharma Pvt. Ltd. - Key offerings
12.13 Pfizer Inc.
Exhibit 161: Pfizer Inc. - Overview
Exhibit 162: Pfizer Inc. - Product / Service
Exhibit 163: Pfizer Inc. - Key news
Exhibit 164: Pfizer Inc. - Key offerings
12.14 Sanofi SA
Exhibit 165: Sanofi SA - Overview
Exhibit 166: Sanofi SA - Business segments
Exhibit 167: Sanofi SA - Key news
Exhibit 168: Sanofi SA - Key offerings
Exhibit 169: Sanofi SA - Segment focus
12.15 Sun Pharmaceutical Industries Ltd.
Exhibit 170: Sun Pharmaceutical Industries Ltd. - Overview
Exhibit 171: Sun Pharmaceutical Industries Ltd. - Product / Service
Exhibit 172: Sun Pharmaceutical Industries Ltd. - Key offerings
12.16 Teva Pharmaceutical Industries Ltd.
Exhibit 173: Teva Pharmaceutical Industries Ltd. - Overview
Exhibit 174: Teva Pharmaceutical Industries Ltd. - Business segments
Exhibit 175: Teva Pharmaceutical Industries Ltd. - Key news
Exhibit 176: Teva Pharmaceutical Industries Ltd. - Key offerings
Exhibit 177: Teva Pharmaceutical Industries Ltd. - Segment focus
12.17 Viatris Inc.
Exhibit 178: Viatris Inc. - Overview
Exhibit 179: Viatris Inc. - Business segments
Exhibit 180: Viatris Inc. - Key news
Exhibit 181: Viatris Inc. - Key offerings
Exhibit 182: Viatris Inc. - Segment focus

13 Appendix

13.1 Scope of the report
13.2 Inclusions and exclusions checklist
Exhibit 183: Inclusions checklist
Exhibit 184: Exclusions checklist
13.3 Currency conversion rates for US$
Exhibit 185: Currency conversion rates for US$
13.4 Research methodology
Exhibit 186: Research methodology
Exhibit 187: Validation techniques employed for market sizing
Exhibit 188: Information sources
13.5 List of abbreviations
Exhibit 189: List of abbreviations

Product Code: IRTNTR77208

Exhibits:

Exhibits1: Executive Summary - Chart on Market Overview
Exhibits2: Executive Summary - Data Table on Market Overview
Exhibits3: Executive Summary - Chart on Global Market Characteristics
Exhibits4: Executive Summary - Chart on Market By Geographical Landscape
Exhibits5: Executive Summary - Chart on Market Segmentation by Drug Class
Exhibits6: Executive Summary - Chart on Market Segmentation by Distribution Channel
Exhibits7: Executive Summary - Chart on Incremental Growth
Exhibits8: Executive Summary - Data Table on Incremental Growth
Exhibits9: Executive Summary - Chart on Vendor Market Positioning
Exhibits10: Parent market
Exhibits11: Market Characteristics
Exhibits12: Offerings of vendors included in the market definition
Exhibits13: Market segments
Exhibits14: Chart on Global - Market size and forecast 2023-2028 ($ million)
Exhibits15: Data Table on Global - Market size and forecast 2023-2028 ($ million)
Exhibits16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
Exhibits17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)
Exhibits18: Historic Market Size - Data Table on global premenstrual syndrome market 2018 - 2022 ($ million)
Exhibits19: Historic Market Size - Drug Class Segment 2018 - 2022 ($ million)
Exhibits20: Historic Market Size - Distribution Channel Segment 2018 - 2022 ($ million)
Exhibits21: Historic Market Size - Geography Segment 2018 - 2022 ($ million)
Exhibits22: Historic Market Size - Country Segment 2018 - 2022 ($ million)
Exhibits23: Five forces analysis - Comparison between 2023 and 2028
Exhibits24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
Exhibits25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
Exhibits26: Threat of new entrants - Impact of key factors in 2023 and 2028
Exhibits27: Threat of substitutes - Impact of key factors in 2023 and 2028
Exhibits28: Threat of rivalry - Impact of key factors in 2023 and 2028
Exhibits29: Chart on Market condition - Five forces 2023 and 2028
Exhibits30: Chart on Drug Class - Market share 2023-2028 (%)
Exhibits31: Data Table on Drug Class - Market share 2023-2028 (%)
Exhibits32: Chart on Comparison by Drug Class
Exhibits33: Data Table on Comparison by Drug Class
Exhibits34: Chart on Analgesics - Market size and forecast 2023-2028 ($ million)
Exhibits35: Data Table on Analgesics - Market size and forecast 2023-2028 ($ million)
Exhibits36: Chart on Analgesics - Year-over-year growth 2023-2028 (%)
Exhibits37: Data Table on Analgesics - Year-over-year growth 2023-2028 (%)
Exhibits38: Chart on Oral contraceptives and ovarian suppression agents - Market size and forecast 2023-2028 ($ million)
Exhibits39: Data Table on Oral contraceptives and ovarian suppression agents - Market size and forecast 2023-2028 ($ million)
Exhibits40: Chart on Oral contraceptives and ovarian suppression agents - Year-over-year growth 2023-2028 (%)
Exhibits41: Data Table on Oral contraceptives and ovarian suppression agents - Year-over-year growth 2023-2028 (%)
Exhibits42: Chart on Antidepressants - Market size and forecast 2023-2028 ($ million)
Exhibits43: Data Table on Antidepressants - Market size and forecast 2023-2028 ($ million)
Exhibits44: Chart on Antidepressants - Year-over-year growth 2023-2028 (%)
Exhibits45: Data Table on Antidepressants - Year-over-year growth 2023-2028 (%)
Exhibits46: Chart on Others - Market size and forecast 2023-2028 ($ million)
Exhibits47: Data Table on Others - Market size and forecast 2023-2028 ($ million)
Exhibits48: Chart on Others - Year-over-year growth 2023-2028 (%)
Exhibits49: Data Table on Others - Year-over-year growth 2023-2028 (%)
Exhibits50: Market opportunity by Drug Class ($ million)
Exhibits51: Data Table on Market opportunity by Drug Class ($ million)
Exhibits52: Chart on Distribution Channel - Market share 2023-2028 (%)
Exhibits53: Data Table on Distribution Channel - Market share 2023-2028 (%)
Exhibits54: Chart on Comparison by Distribution Channel
Exhibits55: Data Table on Comparison by Distribution Channel
Exhibits56: Chart on Retail pharmacies - Market size and forecast 2023-2028 ($ million)
Exhibits57: Data Table on Retail pharmacies - Market size and forecast 2023-2028 ($ million)
Exhibits58: Chart on Retail pharmacies - Year-over-year growth 2023-2028 (%)
Exhibits59: Data Table on Retail pharmacies - Year-over-year growth 2023-2028 (%)
Exhibits60: Chart on Hospital pharmacies - Market size and forecast 2023-2028 ($ million)
Exhibits61: Data Table on Hospital pharmacies - Market size and forecast 2023-2028 ($ million)
Exhibits62: Chart on Hospital pharmacies - Year-over-year growth 2023-2028 (%)
Exhibits63: Data Table on Hospital pharmacies - Year-over-year growth 2023-2028 (%)
Exhibits64: Chart on Online pharmacies - Market size and forecast 2023-2028 ($ million)
Exhibits65: Data Table on Online pharmacies - Market size and forecast 2023-2028 ($ million)
Exhibits66: Chart on Online pharmacies - Year-over-year growth 2023-2028 (%)
Exhibits67: Data Table on Online pharmacies - Year-over-year growth 2023-2028 (%)
Exhibits68: Market opportunity by Distribution Channel ($ million)
Exhibits69: Data Table on Market opportunity by Distribution Channel ($ million)
Exhibits70: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Exhibits71: Chart on Market share By Geographical Landscape 2023-2028 (%)
Exhibits72: Data Table on Market share By Geographical Landscape 2023-2028 (%)
Exhibits73: Chart on Geographic comparison
Exhibits74: Data Table on Geographic comparison
Exhibits75: Chart on North America - Market size and forecast 2023-2028 ($ million)
Exhibits76: Data Table on North America - Market size and forecast 2023-2028 ($ million)
Exhibits77: Chart on North America - Year-over-year growth 2023-2028 (%)
Exhibits78: Data Table on North America - Year-over-year growth 2023-2028 (%)
Exhibits79: Chart on Europe - Market size and forecast 2023-2028 ($ million)
Exhibits80: Data Table on Europe - Market size and forecast 2023-2028 ($ million)
Exhibits81: Chart on Europe - Year-over-year growth 2023-2028 (%)
Exhibits82: Data Table on Europe - Year-over-year growth 2023-2028 (%)
Exhibits83: Chart on Asia - Market size and forecast 2023-2028 ($ million)
Exhibits84: Data Table on Asia - Market size and forecast 2023-2028 ($ million)
Exhibits85: Chart on Asia - Year-over-year growth 2023-2028 (%)
Exhibits86: Data Table on Asia - Year-over-year growth 2023-2028 (%)
Exhibits87: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
Exhibits88: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
Exhibits89: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
Exhibits90: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
Exhibits91: Chart on US - Market size and forecast 2023-2028 ($ million)
Exhibits92: Data Table on US - Market size and forecast 2023-2028 ($ million)
Exhibits93: Chart on US - Year-over-year growth 2023-2028 (%)
Exhibits94: Data Table on US - Year-over-year growth 2023-2028 (%)
Exhibits95: Chart on Germany - Market size and forecast 2023-2028 ($ million)
Exhibits96: Data Table on Germany - Market size and forecast 2023-2028 ($ million)
Exhibits97: Chart on Germany - Year-over-year growth 2023-2028 (%)
Exhibits98: Data Table on Germany - Year-over-year growth 2023-2028 (%)
Exhibits99: Chart on China - Market size and forecast 2023-2028 ($ million)
Exhibits100: Data Table on China - Market size and forecast 2023-2028 ($ million)
Exhibits101: Chart on China - Year-over-year growth 2023-2028 (%)
Exhibits102: Data Table on China - Year-over-year growth 2023-2028 (%)
Exhibits103: Chart on UK - Market size and forecast 2023-2028 ($ million)
Exhibits104: Data Table on UK - Market size and forecast 2023-2028 ($ million)
Exhibits105: Chart on UK - Year-over-year growth 2023-2028 (%)
Exhibits106: Data Table on UK - Year-over-year growth 2023-2028 (%)
Exhibits107: Chart on Japan - Market size and forecast 2023-2028 ($ million)
Exhibits108: Data Table on Japan - Market size and forecast 2023-2028 ($ million)
Exhibits109: Chart on Japan - Year-over-year growth 2023-2028 (%)
Exhibits110: Data Table on Japan - Year-over-year growth 2023-2028 (%)
Exhibits111: Market opportunity By Geographical Landscape ($ million)
Exhibits112: Data Tables on Market opportunity By Geographical Landscape ($ million)
Exhibits113: Impact of drivers and challenges in 2023 and 2028
Exhibits114: Overview on Criticality of inputs and Factors of differentiation
Exhibits115: Overview on factors of disruption
Exhibits116: Impact of key risks on business
Exhibits117: Vendors covered
Exhibits118: Matrix on vendor position and classification
Exhibits119: AbbVie Inc. - Overview
Exhibits120: AbbVie Inc. - Product / Service
Exhibits121: AbbVie Inc. - Key news
Exhibits122: AbbVie Inc. - Key offerings
Exhibits123: Bayer AG - Overview
Exhibits124: Bayer AG - Business segments
Exhibits125: Bayer AG - Key news
Exhibits126: Bayer AG - Key offerings
Exhibits127: Bayer AG - Segment focus
Exhibits128: Eli Lilly and Co. - Overview
Exhibits129: Eli Lilly and Co. - Product / Service
Exhibits130: Eli Lilly and Co. - Key news
Exhibits131: Eli Lilly and Co. - Key offerings
Exhibits132: GlaxoSmithKline Plc - Overview
Exhibits133: GlaxoSmithKline Plc - Business segments
Exhibits134: GlaxoSmithKline Plc - Key news
Exhibits135: GlaxoSmithKline Plc - Key offerings
Exhibits136: GlaxoSmithKline Plc - Segment focus
Exhibits137: Herbalife International of America Inc. - Overview
Exhibits138: Herbalife International of America Inc. - Product / Service
Exhibits139: Herbalife International of America Inc. - Key offerings
Exhibits140: Johnson and Johnson - Overview
Exhibits141: Johnson and Johnson - Business segments
Exhibits142: Johnson and Johnson - Key news
Exhibits143: Johnson and Johnson - Key offerings
Exhibits144: Johnson and Johnson - Segment focus
Exhibits145: Lupin Ltd. - Overview
Exhibits146: Lupin Ltd. - Product / Service
Exhibits147: Lupin Ltd. - Key news
Exhibits148: Lupin Ltd. - Key offerings
Exhibits149: Merck KGaA - Overview
Exhibits150: Merck KGaA - Business segments
Exhibits151: Merck KGaA - Key news
Exhibits152: Merck KGaA - Key offerings
Exhibits153: Merck KGaA - Segment focus
Exhibits154: Novartis AG - Overview
Exhibits155: Novartis AG - Business segments
Exhibits156: Novartis AG - Key offerings
Exhibits157: Novartis AG - Segment focus
Exhibits158: Octavius Pharma Pvt. Ltd. - Overview
Exhibits159: Octavius Pharma Pvt. Ltd. - Product / Service
Exhibits160: Octavius Pharma Pvt. Ltd. - Key offerings
Exhibits161: Pfizer Inc. - Overview
Exhibits162: Pfizer Inc. - Product / Service
Exhibits163: Pfizer Inc. - Key news
Exhibits164: Pfizer Inc. - Key offerings
Exhibits165: Sanofi SA - Overview
Exhibits166: Sanofi SA - Business segments
Exhibits167: Sanofi SA - Key news
Exhibits168: Sanofi SA - Key offerings
Exhibits169: Sanofi SA - Segment focus
Exhibits170: Sun Pharmaceutical Industries Ltd. - Overview
Exhibits171: Sun Pharmaceutical Industries Ltd. - Product / Service
Exhibits172: Sun Pharmaceutical Industries Ltd. - Key offerings
Exhibits173: Teva Pharmaceutical Industries Ltd. - Overview
Exhibits174: Teva Pharmaceutical Industries Ltd. - Business segments
Exhibits175: Teva Pharmaceutical Industries Ltd. - Key news
Exhibits176: Teva Pharmaceutical Industries Ltd. - Key offerings
Exhibits177: Teva Pharmaceutical Industries Ltd. - Segment focus
Exhibits178: Viatris Inc. - Overview
Exhibits179: Viatris Inc. - Business segments
Exhibits180: Viatris Inc. - Key news
Exhibits181: Viatris Inc. - Key offerings
Exhibits182: Viatris Inc. - Segment focus
Exhibits183: Inclusions checklist
Exhibits184: Exclusions checklist
Exhibits185: Currency conversion rates for US$
Exhibits186: Research methodology
Exhibits187: Validation techniques employed for market sizing
Exhibits188: Information sources
Exhibits189: List of abbreviations